Апремиласт (CC-10004, Отесла)
Проводит «Амджен Инк.»
Страница компанииМногоцентровое долгосрочное открытое исследование-продолжение фазы 3b, в котором оценивается апремиласт (CC-10004) у детей в возрасте от 6 до 17 лет (включительно) с бляшечным псориазом среднетяжёлой и тяжёлой степени
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/170/2020-04-21/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование идёт.
- Возраст участников: 6–17 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 100 чел. в стране «Россия».
- Центров в реестре: 15 в 10 городах. Список — ниже на странице.
- Плановое окончание — 03.2027.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 14 · невключение: 14
Критерии включения
- Subject must satisfy the following criteria to be enrolled in the study:
- Subject is male or female 6 to 17 years of age, inclusive, at the time the informed consent document is signed by the legal guardian.
- Subject must have a weight of ≥ 20 kg.
- Subjects must have an age and sex specific BMI value no lower in range than the 5th percentile on the Centers for Disease Control (CDC) growth chart for children and adolescents.
- Subject must have completed Week 52 (Apremilast Extension Phase) of Study CC-10004-PPSO-003.
- Subject is able to sign an assent with a legal guardian/s who understand/s and voluntarily sign/s an informed consent prior to any study-related assessments/procedures being conducted.
- Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
- All female subjects of childbearing potential (FCBP) must either practice abstinence from heterosexual contact or use one of the approved contraceptive options as described below while on apremilast and for at least 28 days after administration of the last dose of apremilast. For the purpose of this study, a female subject is considered of childbearing potential if she is ≥ 12 years old or has reached menarche, whichever occurred first.
- At the time of study entry, and at any time during the study when a female subject of childbearing potential's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding abstinence or contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.
- Females of childbearing potential must have a negative pregnancy test at each visit. All FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
- Option 1: Any one of the following effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy;
- Option 2: Male or female condom or nonlatex condom NOT made out of natural \[animal\] membrane \[for example, polyurethane\]; PLUS one additional barrier method:
- (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
- NOTE: Option 2 may not be acceptable as a contraception option in all countries per local guidelines/regulations.
Критерии невключения
- The presence of any of the following will exclude a subject from enrollment:
- Subject has a condition, including the presence of laboratory abnormalities, or psychiatric illness, that would place the subject at unacceptable risk if he/she were to participate in the study.
- Subject has a condition that confounds the ability to interpret data from the study.
- Subject has evidence of skin conditions, other than psoriasis, that would interfere with clinical assessments.
- Subject is pregnant or breastfeeding.
- Subject has guttate, erythrodermic, or pustular psoriasis.
- Subject has active tuberculosis (TB) or a history of incompletely treated TB.
- Subject answers "Yes" to any question on the Columbia-Suicide Severity Rating Scale at Visit 16 of study CC-10004-PPSO-003.
- Subject plans concurrent use of the following therapies that may have a possible effect on psoriasis.
- Conventional systemic therapy for psoriasis (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, and fumaric acid esters)
- Biologic therapy:
- i. Etanercept (or biosimilar) treatment ii. Adalimumab (or biosimilar) treatment iii. Other TNF or interleukin (IL)-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) iv. Anti-IL-12 or anti-IL-23 treatment (such as ustekinumab, guselkumab, or tildrakizumab) c) Use of any investigational drug other than apremilast
- Subject has prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources.
- Children in Care: a child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.
Источник: ClinicalTrials.gov, NCT04175613 · запись обновлена в реестре 22 декабря 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (6), вторичных — 1
- Adverse Events (AEs) — Up to approximately 4 years
- Columbia-Suicide Severity Rating Scale (C-SSRS) — Collected at each study visit throughout the life of the study - up to 4 years
- Weight of patients treated with Apremilast — Collected at each study visit throughout the life of the study - up to 4 years
- Mean body mass index of the patient treated with Apremilast — Collected at each study visit throughout the life of the study - up to 4 years
- Height patients treated with Apremilast — Collected at each study visit throughout the life of the study - up to 4 years
- Assessment of sexual maturity — Collected every 52 weeks throughout the life of the study - up to 4 years
Цель исследования
This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy.
The study will consist of up to 208 weeks of long-term treatment followed by an 8-week observational follow-up phase.
Области и заболевания
Где проходит
15 центров в 10 городах- ГБУЗ города Москвы «Московский научно-практический Центр дерматовенерологии и косметологии ДЗМ»
- ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России
- ФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава России
- ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России
Откуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 170 от 21.04.2020 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04175613 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
clinmarket · № 8735 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.